Rotasiro® -Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell)

Rotasiro® -Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell)
Product Description

Launched in 2025,  Rotasiro® is the first hexavalent rotavirus vaccine in the world, covering serotypes G1, G2, G3, G4, G8, and G9. It offers six key advantages: exclusive coverage of serotypes G8 and G9, no risk of intussusception, a pure and palatable formulation, breakthrough homogeneous technology, high immunogenicity and robust protective efficacy.

Wuhan Institute of Biological Products

  • Country/Region:
    China
  • Founded:
    1950
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    1000 - 4999
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Specifications
  • Details
    2.0mL per vial. It is a vaccine used to  prevent acute gastroenteritis caused by rotavirus serotypes G1, G2, G3, G4, G8, and G9 in infants.

  • Selling Points
    Convenience; Immune Health; Product Performance; Pure and sweet-tasting formulation for better acceptance in infants
  • Supplied from
    China
  • Measured In
    Container

Wuhan Institute of Biological Products

  • Country/Region:
    China
  • Founded:
    1950
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    1000 - 4999
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical

More Products from Wuhan Institute of Biological Products (2)

Wuhan Institute of Biological Products resources (1)